Alvotech – Global Biopharma Organisation

The Company

Alvotech is a global biopharmaceutical company dedicated to becoming one of the leaders in the biosimilar monoclonal antibody market. Back in 2013, Alvotech announced its plans to invest $500 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. The company’s declared ambition at the time was to become a powerful new player in the field of biopharmaceuticals and it is now well on the road toward achieving that goal.

Click below for more information on:

Or click here to contact Naynesh Mistry to discuss Alvotech in more detail

 

Or find out more about Alvotech here